• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Genscript Biotech Corp (OP: GNNSF )

    1.535 UNCHANGED
    Last Price Updated: 1:35 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 1.535
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 1.535
    Today's Range 1.535 - 1.535
    52wk Range 1.050 - 3.200
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation?
    Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its... 
    Via Benzinga
    Week In Review: Korea's SK Biopharma Acquires Radiopharmaceutical In $571 Million Deal
    In recent news, South Korea’s SK Biopharma in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies of Shanghai in a $571 million deal. 
    Via Talk Markets

    Performance

    YTD
    -25.85%
    -25.85%
    1 Month
    +2.74%
    +2.74%
    3 Month
    +0.85%
    +0.85%
    6 Month
    +3.02%
    +3.02%
    1 Year
    -52.03%
    -52.03%

    More News

    Read More
    Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
    Via Talk Markets
    3 DNA Stocks to Buy for the Synthetic Biology Revolution
    Via InvestorPlace
    The Next Big Disruptors? 3 Biotech Stocks Making Headlines.
    Via InvestorPlace
    Week In Review: Mabwell Out-Licenses Rare Disease Drug For $412.5 Million
    Via Talk Markets
    Three Pharma Stocks to Sell Before They Die
    Via InvestorPlace
    Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact
    Via Talk Markets
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.